Anne Elise Herold Li
Overview
When biotech innovations and licenses lead to conflict—or companies need advice avoiding it—companies trust Anne Li for outside-the-box strategies. She represents clients whose groundbreaking products and services raise complex legal questions at the nexus of competitors and collaborators, including those times when one shifts to the other. She has significant experience in the biotech, pharma, life sciences, and medical device sectors, handling high-stakes litigation in patent, trade secret, and licensing disputes.
Career & Education
- University of Chicago, B.A., psychology
- Emory University, M.P.H.
- Fordham University School of Law, J.D.
- District of Columbia
- New York
- Supreme Court of the United States
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court for the Southern District of New York
- U.S. District Court for the Eastern District of New York
- U.S. District Court for the District of Columbia
- U.S. Patent and Trademark Office (USPTO)
Professional Activities and Memberships
- Vice-Chair, Medical Devices, ABA Science & Technology Law Section, 2017 – 2018
- New York Intellectual Property Law Association
- Executive Committee, William C. Conner Inn of Court
Anne's Insights
Client Alert | 3 min read | 07.22.24
USPTO Offers Updated Guidance on Patent Subject Matter Eligibility for AI
The USPTO has just issued an update to its guidance on subject matter eligibility, discussing the application of these guidelines to emerging technologies such as AI-related and AI-assisted inventions. These guidelines are currently open to public comment until September 16.
Press Coverage | 07.21.24
New Momentum For Bill Limiting Contracts With Chinese Biotech Cos.
Client Alert | 3 min read | 07.16.24
Client Alert | 4 min read | 06.26.24
Representative Matters
- Secured a significant victory (a preliminary injunction against patent infringement through trial) on behalf of Lonza Walkersville Inc. against Israel-based Adva Biotechnology Ltd. in a case involving point-of-care cell-therapy technology.
- Successfully defended Agilent against a preliminary injunction filed by Waters Corp. by demonstrating that Waters was unlikely to succeed on the merits. The case ultimately settled.
- Successfully represented a large pharmaceutical company in a false advertising and unfair competition case.
Anne's Insights
Client Alert | 3 min read | 07.22.24
USPTO Offers Updated Guidance on Patent Subject Matter Eligibility for AI
The USPTO has just issued an update to its guidance on subject matter eligibility, discussing the application of these guidelines to emerging technologies such as AI-related and AI-assisted inventions. These guidelines are currently open to public comment until September 16.
Press Coverage | 07.21.24
New Momentum For Bill Limiting Contracts With Chinese Biotech Cos.
Client Alert | 3 min read | 07.16.24
Client Alert | 4 min read | 06.26.24
Recognition
- The National Law Journal: Emerging Therapies/Life Sciences Trailblazer, 2023
- IAM Patent 1000: Recommended – United States: National, Trade Secret Litigation, 2023
- Law360: Burton Award, Distinguished Legal Writing, 2023
- Chambers USA: Intellectual Property: Patent (Up and Coming) – New York, 2022-2023
Anne's Insights
Client Alert | 3 min read | 07.22.24
USPTO Offers Updated Guidance on Patent Subject Matter Eligibility for AI
The USPTO has just issued an update to its guidance on subject matter eligibility, discussing the application of these guidelines to emerging technologies such as AI-related and AI-assisted inventions. These guidelines are currently open to public comment until September 16.
Press Coverage | 07.21.24
New Momentum For Bill Limiting Contracts With Chinese Biotech Cos.
Client Alert | 3 min read | 07.16.24
Client Alert | 4 min read | 06.26.24
Insights
Can Pharma Firms Deduct Fees In Hatch-Waxman Suits?
|07.18.23
Life Sciences Intellectual Property Review
Patents Or Trade Secrets? How To Choose The Best IP Safeguard For R&D Assets
|05.02.22
Life Science Leader
CRISPR: Maximizing This Revolutionary Genetic Tool While Minimizing IP Risk
|01.26.22
Pharmaceutical Executive
BioPharma – The Calm Between the CRISPR Storms
|01.12.22
Crowell & Moring's Litigation Forecast 2022
"NY Women in Licensing Panel," Crowell & Moring Panel, New York, NY.
|06.28.23
New Momentum For Bill Limiting Contracts With Chinese Biotech Cos.
|07.21.24
Foreign Investment Watch
‘High Stakes’ Litigator Leaves Knobbe For Crowell & Moring
|12.15.23
World Intellectual Property Review
Standing To Sue Can Be Roadblock To Pursuing Patent Infringement Claims
|02.02.22
Technology Transfer Tactics
Motion to Dismiss Based on Trade Secret Disclosure in a Patent for the Birds
|02.22.24
Crowell & Moring’s Trade Secrets Trends
An NDA Leads to the Loss of Trade Secrets, a Failed Deal and No Recourse
|04.21.22
Crowell & Moring’s Trade Secrets Trends
Bad Medicine: Pfizer Files Complaint to Halt Potential COVID-Related Trade Secret Misappropriation
|12.16.21
Crowell & Moring’s Trade Secrets Trends
Who Spilled The (Kidney) Beans? 11th Circuit Unseals Private Emails in Organ Transplant Dispute
|11.30.21
Crowell & Moring’s Trade Secrets Trends
- |
10.07.21
Crowell & Moring’s Trade Secrets Trends
Trade Secret Strategies: Using Standstill Agreements to Resolve Disputes Out of Court
|11.05.20
Crowell & Moring’s Trade Secrets Trends
Coronavirus Related Restrictions on Emergency Trade Secrets Filings in New York
|03.30.20
Crowell & Moring’s Trade Secrets Trends
L’Oreal USA Loss Highlights Importance of Nondisclosure Agreements
|08.15.19
Crowell & Moring's Retail & Consumer Products Law Observer
Don’t Wait Until It’s Too Late: Tardy Trade Secrets Bounced
|05.21.19
Crowell & Moring's Trade Secrets Trends
Practices
- Intellectual Property Litigation
- IP Prosecution and Portfolio Management
- Trade Secrets
- Litigation and Trial
- Trademark Counseling and Litigation
- Patent Litigation
- E-Discovery and Information Management
- U.S. ITC Section 337
- Post-Grant Proceedings
- False Advertising Disputes and Litigation
- Intellectual Property
- Copyright Counseling and Litigation
- Health Care
- Digital Health and Health Information Technology
Anne's Insights
Client Alert | 3 min read | 07.22.24
USPTO Offers Updated Guidance on Patent Subject Matter Eligibility for AI
The USPTO has just issued an update to its guidance on subject matter eligibility, discussing the application of these guidelines to emerging technologies such as AI-related and AI-assisted inventions. These guidelines are currently open to public comment until September 16.
Press Coverage | 07.21.24
New Momentum For Bill Limiting Contracts With Chinese Biotech Cos.
Client Alert | 3 min read | 07.16.24
Client Alert | 4 min read | 06.26.24